Zai Lab Ltd (ZLAB) reports impressive revenue growth and improved net loss, with a strategic focus on global pipeline ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support ...

a monoclonal antibody inhibiting IL-4 and IL-13 activity. The case study followed the progress of an 8-year-old girl with severe AD over a period of 6 months, measuring improvements in skin barrier ...

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway ... EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive ...

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates.

Dr. Cohen-Dayag continued, "In the third quarter of 2024, we received a $30 million milestone payment from our partner Gilead following achieving FDA IND clearance for COM503, a differentiated ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.